8 min read · May 2026
Is Your GLP-1 Provider Going to Survive 2026? A Safety Checklist
Key fact: FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List on April 30, 2026. Over 50 warning letters have been issued to compounders and telehealth companies. Some providers will not survive this regulatory environment.
The GLP-1 telehealth landscape is going through a survival event. The FDA's April 30, 2026 proposal to permanently bar large-scale compounding of GLP-1 drugs signals the end of the shortage-era business model. Here's how to evaluate whether your provider is built to last.
What's Happening
The 503B Bulks List proposal is the final regulatory nail. With semaglutide and tirzepatide already off the shortage list (February 2025 and October 2024 respectively), and the OFA v. FDA lawsuits failing to secure injunctions, there are essentially no legal pathways left for outsourcing facilities to compound these drugs at scale.
503A pharmacies (patient-specific compounding) remain technically legal, but under heavy constraints — including the 4-prescription "safe harbor" limit and aggressive FDA interpretation of what constitutes an "essentially a copy."
Red Flags: Signs Your Provider May Not Survive
1. They source exclusively from 503B outsourcing facilities. If the 503B bulks exclusion is finalized, these pharmacies lose their legal basis overnight.
2. They received an FDA warning letter. Over 50 have been issued since early 2025. Check the FDA warning letters database for your provider's pharmacy partners.
3. They advertise prices that seem impossibly low. Sub-$100/month compounded semaglutide often comes from operations cutting corners on quality, testing, or regulatory compliance.
4. They don't disclose their pharmacy partners. Legitimate telehealth platforms name which pharmacies fill their prescriptions. If you can't find out who's making your medication, that's a problem.
5. They launched after 2024. Many fly-by-night operations entered the market solely to capitalize on the compounding window. They have no infrastructure, clinical credibility, or runway to pivot.
Green Flags: Signs of a Durable Provider
Multiple medication formats. Providers offering injectable, sublingual, and oral options have supply chain flexibility.
Brand-name access. Providers that can prescribe FDA-approved Wegovy, Zepbound, or the new oral Wegovy pill have a regulatory-proof product line.
Board-certified physicians. Not just "licensed providers" — look for obesity medicine board certification or equivalent.
Established track record. Two+ years of operation, visible patient reviews, responsive support.
Providers Built for the Long Haul
Wellorithm
From $147/mo
Board-certified obesity specialists. Multiple medication formats. Established 503A pharmacy relationships.
Compounded medications are not FDA-approved.
Get Started Paid linkSkinnyRx
From $149/mo
Three delivery formats: injectable, sublingual, and tablets. Supply chain diversified.
Compounded medications are not FDA-approved.
Get Started Paid linkSesame Care
Varies
Prescribes FDA-approved brand-name medications only. Immune to compounding regulation changes.
Sources
- FDA. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." April 30, 2026.
- FDA. 50+ warning letters to compounders and telehealth distributors, 2025-2026.
- Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." May 2026.
- HHS. General Counsel referral of Hims to DOJ. February 6, 2026.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.